

Enduring Marathon..
One Vaccine
Lifetime Strength



VAKSIMUNE®
ILT

LIVE ATTENUATED VACCINE AGAINST
INFECTIOUS LARYNGOTRACHEITIS



VAKSIMUNE® ILT

Challenges & Our Commitment:

Infectious Laryngotracheitis (ILT) presents major challenges for poultry farmers. The virus is highly contagious, capable of establishing latency and reactivating under stress, which makes long-term control difficult (Shehata et al., 2013). Clinical signs often mimic other respiratory diseases, complicating diagnosis (Palomino-Tapia et al., 2019), and treatment options are limited to supportive care. Additionally, biosecurity protocols—though essential—can be costly and disruptive to operations.

Vaccination is a critical tool for ILT control. Live CEO-based vaccines provide robust, long-lasting immunity that protects birds throughout their production cycle, especially during high-risk periods such as laying (Saleh, 2014). These vaccines are effective in reducing clinical signs, virus shedding, and mortality, making them essential for maintaining flock health and performance (Hao et al., 2023).

Features:

VAKSIMUNE® ILT is a Freeze dried modified live virus, each dose contains:

Infectious Laryngotracheitis Hudson Strain > 10^{6.5} EID₅₀

VAKSIMUNE® ILT is propagated in embryonated Specific Pathogen Free (SPF) chicken eggs



Vaccination Strategy:

Breeder/Layer: 7-10 Weeks of Age

Vaccine Administration:

Eye Drop, Oral Drop, Drinking water

Packing size: Available in 1000 & 2000 Doses

VAKSIMUNE® ILT Benefits



Long Term Immunity for Breeder & Layer

VAKSIMUNE® ILT vaccine delivers strong immunogenicity, activating both mucosal and systemic immunity for reliable, single-dose protection throughout the laying period. This is key to preventing outbreaks when birds are most vulnerable to respiratory challenges.



Fast Onset of Immunity for Early Protection

Formulated as a CEO (Chicken Embryo Origin)-based live attenuated vaccine, it replicates efficiently in the upper respiratory tract. This enables birds to develop protective immunity within 5-7 days post-vaccination.



Strong Mucosal and Systemic Immune Response

VAKSIMUNE® ILT vaccine induces strong local immunity in the trachea and high virus-neutralizing antibody titers in serum. This dual protection results in reduced clinical signs, virus shedding, and mortality in challenged birds.

Why Did Vaksindo Choose the CEO Vaccine for ILT?

Vaksindo selected the chicken embryo origin (CEO) vaccine over tissue culture origin (TCO) and recombinant vaccines due to its proven superiority in protection and immune response.

1. Stronger and Faster Immunity


CEO vaccines replicate efficiently in the respiratory tract, mimicking natural infection and triggering both mucosal and systemic immunity. In contrast, TCO vaccines replicate poorly, and recombinant vaccines provide slower, less localized protection (Saleh, 2014), (Palomino-Tapia et al., 2019).

2. Superior Field Protection

CEO-vaccinated chickens show fewer symptoms, lower virus shedding, and higher survival after ILTV challenge than those given TCO or recombinant vaccines (Palomino-Tapia et al., 2019), (Hao et al., 2023).

3. Stronger Immune Response

CEO vaccines generate higher virus-neutralizing antibodies and more complete immune activation than TCO or recombinant platforms (Saleh, 2014).



Proven Challenge Test

A field trial on a commercial poultry farm with 1000 pullets evaluated the efficacy of VAKSIMUNE ILT. Group 1 (900 birds) received the vaccine at 8 weeks via eye drop, while Group 2 (100 birds) remained unvaccinated as control. Fourteen days later, 20 birds from each group were challenged with virulent ILT virus. The vaccinated group showed 0% mortality and morbidity, achieving 100% protection. In contrast, the control group showed 40% mortality and 60% morbidity, with typical ILT symptoms like gasping, coughing, and difficulty breathing—proving the strong protection offered by VAKSIMUNE ILT.